Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the target of a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 75,000 shares, a decline of 83.1% from the May 31st total of 445,000 shares. Approximately 0.4% of the shares of the stock are short sold. Based on an average daily volume of 1,295,400 shares, the short-interest ratio is presently 0.1 days.

Insider Transactions at Xilio Therapeutics

In related news, major shareholder Gilead Sciences, Inc. bought 485,250 shares of the company’s stock in a transaction on Tuesday, April 2nd. The stock was bought at an average cost of $0.76 per share, for a total transaction of $368,790.00. Following the acquisition, the insider now directly owns 7,345,473 shares in the company, valued at $5,582,559.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Xilio Therapeutics

A hedge fund recently bought a new stake in Xilio Therapeutics stock. PFG Investments LLC bought a new stake in Xilio Therapeutics, Inc. (NASDAQ:XLO) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned about 0.09% of Xilio Therapeutics as of its most recent filing with the Securities and Exchange Commission. 54.29% of the stock is currently owned by institutional investors and hedge funds.

Xilio Therapeutics Trading Up 0.8 %

NASDAQ:XLO opened at $0.95 on Friday. The company’s 50-day moving average is $1.06 and its two-hundred day moving average is $0.87. Xilio Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.94.

Xilio Therapeutics (NASDAQ:XLO) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.29). Equities research analysts predict that Xilio Therapeutics will post -1.48 EPS for the current year.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.